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ON THE COVER Mary, Queen of
Scots (also known as Mary Stuart, 1542–
1587). By the time she became Queen
at age 19, Mary Stuart’s body had al-
ready aged beyond its years. She had
bouts of heartburn and vomiting. She
developed gastric ulcers, arthritis, ab-
dominal pain, lameness, eyesight problems, and emotional
issues. Her reign lasted just 5 years. Had she lived 300 years
later, Felix Hoppe-Seyler, an early pioneer in what we now
call clinical chemistry, would have looked at her purple urine
and identified the cause of her symptoms. We now know
that Mary, Queen of Scots, suffered from acute intermittent
porphyria, 1 of 10 porphyrias caused by gene abnormalities
that are passed from parents to children. In fact, Mary
passed the disease on to her son, James I, who passed the
disease on to his son Henry. Because of the infrequent oc-
currence of porphyrias in the general population, diagnostic
tests for porphyria are currently performed by specialized
laboratories in many countries. However, data regarding
the analytical and diagnostic performance of these labora-
tories are scarce. In this issue of Clinical Chemistry, Aarsand
and colleagues describe the results of an external quality
assessment program for porphyrin testing. Their results re-
inforce the importance of external quality assessment
schemes as a tool to improve patient care. (See page 1514.)
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